Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan

2024-06-24

临床结果上市批准临床2期细胞疗法免疫疗法

Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan

Preview

来源: Pharmaceutical Technology

The asset previously received SAKIGAKE designation in Japan. Credit: Nemes Laszlo / Shutterstock.

Daiichi Sankyo has announced approval from the Japan Ministry of Health, Labour and Welfare for EZHARMIA (valemetostat tosilate) to treat relapsed or refractory (r/r) peripheral T-cell lymphoma (PTCL).

EZHARMIA is the first dual EZH1 and EZH2 inhibitor to receive approval for this indication.

The asset previously received the SAKIGAKE designation.

Its approval is grounded in the outcomes of the global, open-label, single-arm, two-cohort VALENTINE-PTCL01 Phase II trial.

The trial assessed the efficacy and safety of EZHARMIA in patients with relapsed or refractory PTCL and adult T-cell leukemia/lymphoma who had previously undergone at least one systemic therapy and were ineligible for a hematopoietic stem cell transplant at screening.

See Also:Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease

Preview

来源: Pharmaceutical Technology

AstraZeneca’s Truqap and Faslodex combo receives approval in EU

Preview

来源: Pharmaceutical Technology

It enrolled 133 patients across multiple sites in Europe, Asia, North America and Oceania,

The primary endpoint of the trial was objective response rate (ORR) with secondary endpoints being the duration of response, complete response (CR), partial response (PR), duration of CR, progression-free survival, overall survival, safety and pharmacokinetics.

In the study, EZHARMIA demonstrated an ORR of 43.7% in 119 efficacy-evaluable patients with relapsed or refractory PTCL.

The treatment also led to 17 CRs and 35 PRs, with responses observed across various PTCL subtypes, including angioimmunoblastic T-cell lymphoma, PTCL not otherwise specified and other PTCL subtypes.

Daiichi Sankyo Japan research and development division head and executive officer Toshinori Agatsuma stated: “This second indication for EZHARMIA in Japan is an important advance for the treatment of relapsed or refractory peripheral T-cell lymphoma, as new and effective treatment options are needed to improve patient outcomes. EZHARMIA exemplifies the innovative research being conducted by Daiichi Sankyo aimed at creating new medicines with the potential to change the standard of care for patients with cancer.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构